相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Profiling of dalcetrapib metabolites in human plasma by accelerator mass spectrometry and investigation of the free phenothiol by derivatisation with methylacrylate
Christophe Husser et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2018)
Present therapeutic role of cholesteryl ester transfer protein inhibitors
Nicola Ferri et al.
PHARMACOLOGICAL RESEARCH (2018)
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
A. Michael Lincoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination
R. Krishna et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
HDL function is impaired in acute myocardial infarction independent of plasma HDL cholesterol levels
Wijtske Annema et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
Jean-Claude Tardif et al.
Circulation-Cardiovascular Genetics (2015)
Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches
David S. Small et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
Jean-Claude Tardif et al.
Circulation-Cardiovascular Genetics (2015)
Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease
Antonio M. Gotto et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Evidence for a role of CETP in HDL remodeling and cholesterol efflux: Role of cysteine 13 of CETP
Cyrille Maugeais et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2013)
Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dalcetrapib Altered Distribution of the Active Thiol?
Mary Phelan et al.
CLINICAL PHARMACOKINETICS (2013)
In vivo evaluation of drug-drug interactions linked to UGT inhibition: the effect of probenecid on dalcetrapib pharmacokinetics
Pau Aceves Baldo et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study
Christie M. Ballantyne et al.
AMERICAN HEART JOURNAL (2012)
No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30)
Annie Young et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2012)
Solubility and stability of dalcetrapib in vehicles and biological media
Guenter Gross et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
Evidence of a Drug-Drug Interaction Linked to Inhibition of Ester Hydrolysis by Orlistat
Darren Bentley et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2012)
New molecular insights into CETP structure and function: a review
M. Arthur Charles et al.
JOURNAL OF LIPID RESEARCH (2012)
Determination of dalcetrapib by liquid chromatography-tandem mass spectrometry
Katja Heinig et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects A Randomized, Double-Blind, Placebo-Controlled, Phase I Study
Michael Derks et al.
CLINICAL DRUG INVESTIGATION (2011)
Effects of Food Intake on the Pharmacokinetic Properties of Dalcetrapib: Findings From Three Phase I, Single-Dose Crossover Studies in Healthy Volunteers
Michael Derks et al.
CLINICAL THERAPEUTICS (2011)
Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe
Michael Derks et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Future Therapeutic Directions in Reverse Cholesterol Transport
Amit V. Khera et al.
CURRENT ATHEROSCLEROSIS REPORTS (2010)
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
M. John Chapman et al.
EUROPEAN HEART JOURNAL (2010)
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
Evan A. Stein et al.
EUROPEAN HEART JOURNAL (2010)
Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing
Michael Derks et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin
Michael Derks et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Functions of cholesterol ester transfer protein and relationship to coronary artery disease risk
Alan R. Tall
JOURNAL OF CLINICAL LIPIDOLOGY (2010)
Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drug-Drug Interactions
Michael Derks et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Biochemical characterization of cholesteryl ester transfer protein inhibitors
Mollie Ranalletta et al.
JOURNAL OF LIPID RESEARCH (2010)
Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
Gregory G. Schwartz et al.
AMERICAN HEART JOURNAL (2009)
Safety and Tolerability of Dalcetrapib
Evan A. Stein et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats
E. S. G. Stroes et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
A Single-Center, Open-Label, One-Sequence Study of Dalcetrapib Coadministered With Ketoconazole, and an In Vitro Study of the S-Methyl Metabolite of Dalcetrapib
Michael Derks et al.
CLINICAL THERAPEUTICS (2009)
In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates
Michael Derks et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Biophysical and biochemical approach to locating an inhibitor binding site on cholesteryl ester transfer protein
David Cunningham et al.
BIOCONJUGATE CHEMISTRY (2008)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with Pravastatin in type II dyslipidemia
JA Kuivenhoven et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein
H Shinkai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
H Okamoto et al.
NATURE (2000)
分享论文
